Jazz Pharmaceuticals (NASDAQ:JAZZ) Announces Earnings Results, Beats Expectations By $0.17 EPS

Jazz Pharmaceuticals (NASDAQ:JAZZ) released its quarterly earnings data on Monday. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.05) by $0.17, FiscalAI reports. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion.

Here are the key takeaways from Jazz Pharmaceuticals’ conference call:

• Positive Sentiment: Jazz reported record third-quarter revenue of $1.24 billion, up 10% year over year, and raised 2026 revenue guidance to $4.775 billion–$4.85 billion. The company cited broad commercial execution across sleep, oncology and international markets while keeping operating-expense guidance unchanged.
• Positive Sentiment: Ziihera’s launch in first-line HER2-positive metastatic gastroesophageal adenocarcinoma generated $21 million in third-quarter sales and showed strong early community adoption, including a threefold increase in new ordering accounts in September. Jazz estimates a 3,000–4,000-patient annual U.S. addressable population and increased Ziihera’s peak-sales potential to $3 billion–$5 billion.
• Positive Sentiment: Xywav sales rose 12% to $483 million, with approximately 425 net patient additions during the quarter. Management said high-sodium oxybate generics have had limited impact so far and expects Xywav’s low-sodium profile and clinical differentiation to support continued durability into 2027.
• Positive Sentiment: Jazz completed its $820 million acquisition of Actio Biosciences, adding ABS-1230, a precision epilepsy therapy targeting KCNT1 mutations. Initial patient efficacy data are expected this quarter, while the company also advanced its orexin-2 agonist JZP269 into a Phase I trial.
• Negative Sentiment: Zepzelca faces a likely competitive headwind in 2027 from Amgen’s IMDELLTRA following strong first-line maintenance small-cell lung cancer data, although management expects no impact to 2026 guidance. Modeyso revenue growth may also proceed at a more measured pace as Jazz expands from academic centers into community oncology ahead of the ACTION trial readout in the first half of 2027.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock traded down $1.54 during trading hours on Monday, reaching $214.44. 1,042,884 shares of the company were exchanged, compared to its average volume of 931,315. The firm has a market cap of $13.92 billion, a price-to-earnings ratio of 14.79, a PEG ratio of 0.43 and a beta of 0.38. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. The stock has a 50-day moving average of $231.96 and a 200 day moving average of $216.24. Jazz Pharmaceuticals has a 12 month low of $128.80 and a 12 month high of $266.38.

Insider Buying and Selling

In other news, EVP Robert Iannone sold 76,921 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the transaction, the executive vice president owned 65,686 shares of the company’s stock, valued at $16,401,794.20. This trade represents a 53.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce Cozadd sold 6,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $250.13, for a total transaction of $1,500,780.00. Following the completion of the sale, the director owned 351,875 shares of the company’s stock, valued at $88,014,493.75. The trade was a 1.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 94,121 shares of company stock worth $23,337,922. 4.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. The Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a research note on Thursday, September 24th. They issued a “buy” rating and a $337.00 price target for the company. Royal Bank Of Canada cut their price objective on shares of Jazz Pharmaceuticals from $299.00 to $296.00 and set an “outperform” rating on the stock in a research report on Thursday, October 8th. UBS Group lifted their target price on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a “buy” rating in a research note on Friday, September 11th. Wells Fargo & Company boosted their target price on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Finally, Piper Sandler boosted their target price on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $292.05.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.